Released Presentations
PLENARY SESSIONS

THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM REGULATORY DECISIONS

Presentation
Shelby D. Reed, 2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Bennett Levitan, Senior Director, Benefit-risk Assessment, Department of Epidemiology, Janssen Research & Development, Titusville, NJ, USA
Matt Reaney, Global Head of Clinical Outcomes, Sanofi, Guildford, Surrey, UK
Jeff Shuren, Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA

 

ISSUE PANEL PRESENTATIONS

IP1 : DESIGNING A PATIENT-CENTERED VALUE FRAMEWORK TO GUIDE SHARED DECISION MAKING IN ONCOLOGY: WHY, WHAT, AND HOW?

Presentation
Henry A. Glick, Professor of Medicine, Perelman School of Medicine; Professor of Health Care Systems, Wharton School, University of Pennsylvania, Philadelphia, NY, USA
Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Presentation
Ellen Sonet, Chief Strategy and Alliance Officer, Strategy, CancerCare, New York, NY, USA
Presentation
Jalpa A. Doshi, Professor of Medicine, Perelman School of Medicine; Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA

 

IP2 : WHAT ROLE FOR VALUE ASSESSMENT IN US PRIVATE PAYERS’ SPECIALTY DRUG COVERAGE DECISIONS?

Presentation
James D. Chambers, Associate Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Susan A. Cantrell, Chief Executive Officer, Academy of Managed Care Pharmacy, Alexandra, VA, USA
Randy Burkholder, Vice President of Policy and Research, PhRMA, Washington, DC, USA
Sara Traigle van Geertruyden, Executive Director, Partnership to Improve Patient Care, Washington, DC, USA

 

IP4 : INCORPORATING QUANTITATIVE PATIENT PREFERENCE INFORMATION INTO HEALTHCARE DECISION-MAKING PROCESSES: IS HEALTH TECHNOLOGY ASSESSMENT FALLING BEHIND?

Presentation
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research, Professor, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Paula Lorgelly, Deputy Director, Office of Health Economics, London, UK
A. Brett Hauber, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
David J. Mott, Economist, Office of Health Economics, London, UK

 

IP5 : SHOULD WE MOVE BEYOND CONVENTIONAL COST-EFFECTIVENESS ANALYSIS? IF SO, HOW?

Presentation
Peter J. Neumann, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Darius N. Lakdawalla, Quintiles Chair, Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Jeroen P Jansen, Lead Scientific Advisor - Open Source Value Project, Innovation and Value Initiative; Precision Health Economics, Los Angeles, CA, USA

 

IP6 : INCREASING MEDICAL DEVICE EVIDENCE FOR PAYERS, PROVIDERS, AND HTA BODIES: WHO’S RESPONSIBLE FOR GENERATING THE EVIDENCE?

Presentation
Bruce Gingles, Vice President, Global Technology Assessment and Healthcare Policy, Cook Medical, Bloomington, IN, USA
Karen Worley, Research Manager, Comprehensive Health Insights, Humana, Cincinnati, OH, USA
Suzanne Belinson, Executive Director, Blue Cross and Blue Shield Association, Chicago, IL, USA
Harindra C Wijeysundera, Vice President, Medical Devices and Clinical Interventions, CADTH, Ottawa, ON, Canada

 

IP7 : THE CHANGING LANDSCAPE OF HEALTHCARE DECISION MAKING: HOW CAN WE LEVERAGE THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY, COVERAGE, AND CLINICAL DECISION MAKING?

Presentation
Rachael Fleurence, Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Owen Faris, Clinical Trials Director, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA
Kathleen Blake, Vice President, Healthcare Quality, American Medical Association (AMA), Washington, DC, USA
Daniel Caños, Senior Epidemiologist, Office of Clinical Standards and Quality, Coverage and Analysis Group, Centers for Medicare & Medicaid Services, Washington, DC, USA

 

IP8 : HOW IMPORTANT ARE CORE OUTCOME SETS TO MEASURING VALUE OF INNOVATIVE NEW DRUGS?

Presentation
Elise Berliner, Director, Technology Assessment Program, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA
Presentation
Sean R Tunis, President and Chief Executive Officer, Center for Medical Technology Policy, Baltimore, MD, USA
Presentation
Elizabeth Seeley, Adjunct Lecturer on Health Policy and Management, Department of Health Policy and Management, TH Chan School of Public Health, Harvard University, Boston, MA, USA

 

IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED

Presentation
Neil Hawkins, Professor of Health Technology Assessment (HTA), Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
Presentation
J. Jaime Caro, Chief Scientist, Evidera, Waltham, MA, Professor in Practice, London School of Economics, and Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal, QC, Canada
Presentation
Renée J G Arnold, Director, Life Sciences, Navigant Consulting, Inc., San Francisco, CA, USA

 

IP10 : PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?

Presentation
Jalpa A. Doshi, Professor of Medicine, Perelman School of Medicine; Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA
Presentation
Steven Miller, Senior Vice President and Chief Medical Officer, Express Scripts, St. Louis, MO, USA
Presentation
Seth J. Baum, President, Affiliate Professor of Medicine, Schmidt College of Medicine, Florida Atlantic University (FAU), American Society for Preventive Cardiology; Chief Medical Officer, Excel Medical Clinical Trials, Boca Raton, FL, USA
Presentation
Cat Davis Ahmed, Vice President, Policy and Outreach, The FH Foundation, Pasadena, CA, USA

 

IP11 : “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (Invited Issue Panel)

Presentation
Stacie B. Dusetzina, Associate Professor, Health Policy, Ingram Associate Professor of Cancer Research, Vanderbilt University School of Medicine, Nashville, TN, USA
Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA

 

IP12 : WHAT RESEARCH SHOULD BE UNDERTAKEN TO SUPPORT DECISIONS REGARDING THE VALUE OF CURING OR ERADICATING DISEASE?

Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Presentation
Carleigh B Krubiner, Research Scholar and Project Director, Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA

 

IP13 : SURROGATE OUTCOMES IN ONCOLOGY: HOW CAN THEY BE USED TO PREDICT OVERALL SURVIVAL IN CLINICAL PRACTICE AND PAYER DECISION MAKING?

Presentation
Louis P. Garrison, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA

 

IP16 : IN THE ELECTRONIC HEALTH RECORD ERA, DO WE STILL NEED CLINICAL REGISTRIES?

Presentation
Lisa M. Wruck, Director, Center for Predictive Medicine, Duke Clinical Research Institute, Durham, NC, USA
Sharon Hensley Alford, Associate Chief Health Officer, IBM Watson Health, Cambridge, MA, USA
Marc Berger, Consultant, Self Employed, New York, NY, USA
Matthew T. Roe, Professor of Medicine, Duke Clinical Research Institute, Duke University, Durham, NC, USA

 

IP17 : HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?

Presentation
Cynthia Iglesias, Senior Research Fellow, Centre for Health Economics, University of York, York, UK
Presentation
Katarzyna Kolasa, Professor of Health Economics, Head of Department, Health Economics and Healthcare Management, Kozminski University, Warszawa, Poland

 

IP19 : VALUE ASSESSMENT FRAMEWORKS IN AN ERA OF PERSONALIZED MEDICINE: SHARED OBJECTIVES OR IRRECONCILABLE DIFFERENCES?

Presentation
Robert W Dubois, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA
Kristen Migliaccio-Walle, Director, Global Health Economics & Outcomes Research, Xcenda, LLC, Palm Harbor, FL, USA
Sara Traigle van Geertruyden, Executive Director, Partnership to Improve Patient Care, Washington, DC, USA
Daniel A Ollendorf, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

 

IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION

Presentation
Mike Ciarametaro, Vice President, National Pharmaceutical Council, Washington, DC, USA
Presentation
Ilene L. Hollin, Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics, Washington, DC, USA
Presentation
Josh Seidman, Senior Vice President, Avalere, Washington, DC, USA

 

IP22 : CHALLENGES AND OPPORTUNITIES IN THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING FOR IN VITRO DIAGNOSTICS

Presentation
Tyler J. O'Neill, Scientist, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA
Asif Jan, Lead, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA
Brad Spring, Vice President, Regulatory Affairs, BD Life Sciences, Sparks, MD, USA
Michael S. Waters, SHIELD Team Lead; CDRH RWE Tactical Team – Diagnostics, Office of in vitro Diagnostics and Radiologic Health (OIR), Food and Drug Administration (FDA), Silver Spring, MD, USA

 

IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

Presentation
Kathryn Lasch, Executive Director, Patient Reported Outcomes, Pharmerit International, Newton, MA, USA
Presentation
Helen Kitchen, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK
Presentation
Katy Benjamin, Director, HEOR - Patient Reported Outcomes, Abbvie Inc, Chicago, IL, USA
Presentation
Helen Doll, Strategic Lead, Quantitative Science, Clinical Outcomes Solutions, Folkestone, UK

 

WORKSHOP PRESENTATIONS

W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

Presentation
Scott D. Ramsey, Director, Public Health Sciences, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
Presentation
Pralay Mukhopadhyay, Statistician, AstraZeneca, Gaithersburg, MD, USA
Presentation
Yiduo Zhang, Director, Health Economics and Payer Analytics, Global Payer Evidence and Pricing, AstraZeneca, Gaithersburg, MD, USA

 

W2 : WHAT IS PATIENT EXPERIENCE DATA? THE REGULATORY PERSPECTIVE

Presentation
Martin Ho, Associate Director for Quantitative Innovation, Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Springs, MD, USA
Megan Moncur, Senior Advisor, Science of Patient Input, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, USA
Pujita Vaidya, Director (Acting), Decision Support and Analysis Team, Office of Strategic Programs/Office of Program and Strategic Analysis, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, USA
Elektra Papadopoulos, Associate Director, Clinical Outcome Assessments Staff, Office of New Drugs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, USA

 

W3 : DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE

Presentation
Murray Aitken, Executive Director, IQVIA Institute for Human Data Science, New York, NY, USA
Karen Schoelles, Director, ECRI Institute HTA Consulting Service, ECRI Institute, Plymouth Meeting, PA, USA
Penny Mohr, Senior Advisor, Emerging Technology and Delivery System Innovation Research Initiatives, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Jasmine Bihm, Staff Fellow, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
Presentation
Murray Aitken, Executive Director, IQVIA Institute for Human Data Science, New York, NY, USA
Karen Schoelles, Director, ECRI Institute HTA Consulting Service, ECRI Institute, Plymouth Meeting, PA, USA
Penny Mohr, Senior Advisor, Emerging Technology and Delivery System Innovation Research Initiatives, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Jasmine Bihm, Staff Fellow, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

 

W4 : BIOSIMILARS, UTILIZATION, AND POST-MARKETING SURVEILLANCE IN THE UNITED STATES (Invited Workshop)

Presentation
Cate Lockhart, Program Director, Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA, USA
Mark J. Cziraky, Vice President of Research, Healthcore, Wilmington, DE, USA
Mike Blum, Deputy Director, Office of Pharmacovigilance and Epidemiology, U.S. Food & Drug Administration, Silver Spring, MD, USA

 

W6 : ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS

Presentation
Josephine Mauskopf, Vice President, Health Economics, RTI Health Solutions, Durham, NC, USA
David E Bloom, Clarence James Gamble Professor of Economics and Demography, TH Chan School of Public Health, Harvard University, Boston, MA, USA
Presentation
Americo Cicchetti, Professor/Director, Graduate School of Health Economics and Management, Università Cattolica del Sacro Cuore, Rome, Italy

 

W7 : ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE: DOES THE HEALTH ECONOMIST NEED TO ADAPT TO THE MACHINE?

Presentation
Amine Aissaoui, Researcher, LEDA-LEGOS, Paris Dauphine University, PSL, Paris, France
Olivier Ethgen, Scientific Director, SERFAN innovation, Namur, Belgium
Patricia A Deverka, Senior Researcher, American Institutes for Research, Chapel Hill, NC, USA
Augustin Terlinden, Actuary and Health Economist, Consultant, Paris, France

 

W8 : ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS

Presentation
Heather Adams, Associate Professor, Department of Neurology & Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
Presentation
Elektra Papadopoulos, Associate Director, Clinical Outcome Assessments Staff, Office of New Drugs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, USA

 

W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)

Presentation
Jui-Chen Yang, Research Economist, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA
Presentation
Kevin Marsh, Executive Director, Outcomes Research, Evidera Ltd, London, UK
Presentation
Kathryn O’Callaghan, Assistant Director of Strategic Programs, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA

 

W10 : MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE

Presentation
Paul Melmeyer, Director of Federal Policy, National Organization for Rare Disorders (NORD), Washington, DC, USA
Presentation
Louis P. Garrison, Professor Emeritus, University of Washington, Seattle, WA, USA

 

W11 : CHOOSING THE APPROPRIATE MODELING METHOD: CAUSAL MODELING, HEALTH ECONOMIC MODELING, CONSTRAINED OPTIMIZATION OR SIMULATION?

Presentation
Praveen Thokala, Research Fellow, The University of Sheffield, Sheffield, UK
Deborah A Marshall, Professor, University of Calgary, Calgary, AB, Canada
Kalyan S. Pasupathy, Faculty, Healthcare Policy & Research and Co- Scientific Director, Healthcare Systems Engineering Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA
William H Crown, Chief Scientific Officer, OptumLabs, Cambridge, MA, USA

 

W12 : COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA (Advanced Workshop)

Presentation
Sherri Rose, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Presentation
Amanda Mejia, Assistant Professor, Department of Statistics, Indiana University, Bloomington, IN, USA
Presentation
Laura Hatfield, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Presentation
Alisa Stephens-Shields, Assistant Professor, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

 

W13 : WHAT IS PATIENT-CENTERED AND FIT-FOR-PURPOSE PATIENT PREFERENCE INFORMATION?

Presentation
Anindita Saha, Director, External Expertise and Partnerships, Center for Devices & Radiological Health (CDRH), US Food & Drug Administration, Silver Spring, MD, USA
A. Brett Hauber, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
Stephanie Christopher, Program Director, Medical Device Innovation Consortium, Arlington, VA, USA
Margaret Sheehan, Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA

 

W14 : NETWORK META-ANALYSIS FOR VARIOUS STUDY DESIGNS: STEPPING OUTSIDE THE RANDOMIZED CONTROLLED TRIALS COMFORT ZONE INTO THE REAL WORLD

Presentation
Christopher Schmid, Professor of Biostatistics, School of Public Health, Brown University, Providence, RI, USA
Andreas Karabis, Principal, RWES, IQVIA, Amsterdam, The Netherlands
Ashley Pitcher, Engagement Manager, IQVIA, London, UK

 

W15 : PATIENT INVOLVEMENT THROUGHOUT THE STAGES OF PATIENT-REPORTED OUTCOME DEVELOPMENT AND CLINICAL TRIAL IMPLEMENTATION

Presentation
Ann Hartry, Vice President, Health Economics and Outcomes Research (HEOR), Lundbeck, Deerfield, IL, USA
Helen Kitchen, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK
Sarah L Knight, Consultant, Clinical Outcomes Assessment Team, DRG Abacus, Bicester, UK
Cindy Coney, President, and Patient Advocate, Monarch Training and Consulting, Tampa, FL, USA

 

W16 : CHOOSING HOW TO CHOOSE: COLLECTIVE DECISION MAKING IN HEALTHCARE ORGANIZATIONS

Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Guru Madhavan, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

 

W17 : DO CUTTING-EDGE ONE-TIME TREATMENTS NEED EQUALLY INNOVATIVE-, OUTCOMES-, OR ANNUITY-BASED PAYMENT MODELS?

Presentation
Omar Ali, Pharmacy Director, QIPP Adviser Commissioning Payer Network & former ERG Cost Impact Modelling, NICE, London, UK
Mark Chalmers, Principal & EU Lead, CBPartners, London, UK
Andrew Gould, Principal, CBPartners, New York, NY, USA
Maximilian Hunt, Principal, CBPartners, New York, NY, USA

 

W18 : OPEN SOURCE SOFTWARE FOR BUILDING HEALTH ECONOMIC MODELS

Presentation
Joseph F Levy, Postdoctoral Fellow, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Erik J Dasbach, Executive Director, Outcomes Research, Merck & Co. Inc., Kenilworth, NJ, USA
Presentation
Fernando Alarid-Escudero, Post-Doctoral Associate, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA

 

W19 : MEDICAL DEVICE REAL-WORLD EVIDENCE FOR BEGINNERS: A PRIMER

Presentation
Stephen S Johnston, Director, Johnson & Johnson, Inc., New Brunswick, NJ, USA
Frank R. Ernst, Executive Director, Real-World Evidence, CTI Clinical Trial and Consulting Services, Covington, KY, USA
Abhishek S Chitnis, Associate Director, Epidemiology, Medical Devices, Real World Analytics and Research, Johnson & Johnson, New Brunswick, NJ, USA
Joshua Gagne, Associate Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics; Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

 

W20 : FIXING THE TOWER OF BABEL: ESTABLISHING A COMMON METRIC FOR PATIENT-REPORTED OUTCOME MEASURES

Presentation
Jakob B. Bjorner, CSO, Optum Patient Insights, Johnston, RI, USA
Presentation
Felix Fischer, Researcher, Department for Psychosomatic Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
Presentation
Benjamin D. Schalet, Research Assistant Professor of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Presentation
Ian Kudel, Senior Scientist, Optum Patient Insights, Johnston, RI, USA

 

W21 : PRINCIPLES OF EFFECTIVE MACHINE LEARNING APPLICATIONS IN REAL WORLD EVIDENCE

Presentation
Andrew Cox, Research Scientist, Data Analytics, Evidera, London, UK
David J. Vanness, Associate Professor, Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
Gorana Capkun-Niggli, Head of HEOR Innovation, Novartis Pharma AG, Basel, Switzerland
Sreeram Ramagopalan, Director, Center for Observational Research and Data Sciences (CORDS), Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK

 

W22 : THE MEDIUM IS THE MESSAGE: USING INTERACTIVE GRAPHICS TO EFFECTIVELY COMMUNICATE HEALTH ECONOMICS AND OUTCOMES RESEARCH FINDINGS

Presentation
Shelagh M Szabo, Principal and Scientific Director, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
Andrew Lloyd, Director, Acaster Lloyd Consulting Ltd., London, UK
Bonnie M Donato, Senior Director, Global Health Outcomes, Alexion Pharmaceuticals, Inc, New Haven, CT, USA
Ross Tsuyuki, Professor, University of Alberta, Edmonton, AB, Canada

 

W23 : ESTIMATING THE COST OF ADVERSE EVENTS IN ECONOMIC MODELS: A DISCUSSION OF REAL-WORLD DATA VERSUS TREATMENT GUIDELINES BASED METHODOLOGIES

Presentation
Josh J. Carlson, Associate Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Martin Cloutier, Manager, Analysis Group, Inc., Montreal, QC, Canada
William Wong, Sr. Health Economist, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA

 

ISPOR FORUMS

F1 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING

Presentation
A. Simon Pickard, Professor, Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA
Andrew Lloyd, Director, Acaster Lloyd Consulting Ltd., London, UK
John E. Brazier, Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Bruce Crawford, Vice President, Real World Evidence, APAC, Syneos Health, Tokyo, Japan

 

F2 : HANDLING MISSING VALUES IN REAL-WORLD DATA: ARE THERE CHALLENGES FOR REGULATORY DECISIONS FOR MEDICAL PRODUCTS?

Presentation
Judith J. Stephenson, Principal Scientist, Survey Research, HealthCore, Inc., Wilmington, DE, USA
Samuel Wilson, Associate Director-Statistics, Astellas Pharmaceuticals US, Inc., Northbrook, IL, USA
Helene Karcher, Managing Vice-President and Global Head of Modeling, Analytica Laser, Basel, Switzerland
Laurence Djatche, Health Economics and Outcomes Research Post-Doctoral Fellow, College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA
Nneka C. Onwudiwe, PRO/PE Scientific Reviewer, US Food and Drug Administration, Silver Spring, MD, USA

 

F3 : DEFINING PATIENT CENTEREDNESS AND ENGAGEMENT IN HEOR: PROPOSED DEFINITION AND STAKEHOLDER RESPONSE

Presentation
Rachel L. Harrington, Pre-Doctoral Fellow, Institute for Health Research and Policy/College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
Eleanor M. Perfetto, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland School of Pharmacy, Baltimore, MD, USA
Suzanne Schrandt, Director, Patient Engagement, Arthritis Foundation, Atlanta, GA, USA
Sarah Donelson, Lead, Patient-Centered Research, Genentech, San Francisco, CA, USA

 

F4 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR

Presentation
James F. Murray, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA
Laura T. Pizzi, Professor and Director, Center for Health Outcomes Policy and Economics, Rutgers University, Piscataway, NJ, USA
Bill Marder, Chief Data Strategist, IBM Watson Health, Cambridge, MA, USA

 

F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK

Presentation
Boxiong Tang, Senior Director, Global Health Economics and Outcomes Research (GHEOR), Teva Pharmaceutical, Frazer, PA, USA
Presentation
Jianwei Xuan, Professor and Director, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China
Presentation
Sang-Soo Lee, Director, Corporate Affairs, Medtronic Korea, Seoul, Korea, Republic of (South)

 

F6 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS

Presentation
James F. Murray, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA
Anirban Basu, Stergachis Family Endowed Professor & Director, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA
Rachael Fleurence, Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Gillian D Sanders Schmidler, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, The Robert J. Margolis, MD, Center for Health Policy, Duke University, Washington, DC, USA
Lotte Steuten, Associate Professor & Director, Health Economics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

 

F7 : ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN

Presentation
Richard J. Willke, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA
Laura T. Pizzi, Professor and Director, Center for Health Outcomes Policy and Economics, Rutgers University, Piscataway, NJ, USA
Brian Ung, Post-Doctoral Fellow, US Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, USA
Jason Harris, Associate Director of Policy and Programs, National Health Council, Washington, DC, USA

 

F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

Presentation
Bor-Sheng Ko, Attending Physician and Clinical Assistant Professor, BMT Unit and Hematology Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Presentation
Jianwei Xuan, Director, Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China
Presentation
Jitendar Sharma, CEO, Andhra Pradesh MedTech Zone Limited, Andhra Pradesh, India
Presentation
Sukyeong Kim, Senior Research Fellow, Evidence-based Research Department, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)
Presentation
Makoto Kobayashi, Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan

 

F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

Presentation
Boxiong Tang, Senior Director, Global Health Economics and Outcomes Research (GHEOR), Teva Pharmaceutical, Frazer, PA, USA
Presentation
Louis Garrison, Professor Emeritus, CHOICE Institute, University of Washington, Seattle, WA, USA
Presentation
Juan Carlos Alandete Manotas, MACS LATAM, Bayer, Whippany, NJ, USA
Presentation
Ramiro E. Gilardino, Director, Global Networks Latin America, ISPOR, Lawrenceville, NJ, USA

 

EDUCATIONAL SYMPOSIA

HEALTHCARE GRIDLOCK BETWEEN VALUE, AFFORDABILITY, AND ACCESS: THE GOOD, THE BAD AND THE UGLY

Presentation
Diana Brixner, Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes, University of Utah, Salt Lake City, UT, USA
Jeff Dunn, Vice President, Magellan RX, Salt Lake City, UT, USA
Sara Carruth, Manager in Health Economic and Outcomes, MedImpact Healthcare Systems, San Diego, CA, USA
David Harrison, Director, Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA

 

ROLES OF BIOSIMILARS ON PATIENT ACCESS

Presentation
Edmund J. Pezalla, Former President, Aetna, Wethersfield, CT, USA
HoUng Kim, Head of Strategy and Operation Divisions, Celltrion Healthcare, Incheon, Korea, Republic of (South)
Jørgen Jahnsen, Professor, Gastroenterology, Akershus University Hospital, Lørenskog, Norway
Laszlo Gulacsi, Head of Department/Professor, Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary

 

21st CENTURY CURES ACT AND THE FUTURE OF REAL-WORLD EVIDENCE

Presentation
Jennifer S. Graff, Vice President, National Pharmaceutical Council, Washington, DC, USA
David Thompson, Senior Vice President, Real World & Late Phase, Syneos Health, Boston, MA, USA
Cathy W Critchlow, Vice President, Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA
David Martin, Captain, U.S. Public Health Service; Associate Director for Real World Evidence Analytics, U.S. Food and Drug Administration, Office of Medical Policy, Center for Drug Evaluation and Research, Silver Spring, MD, USA

 

BRIDGING THE GAP BETWEEN RETROSPECTIVE DATA AND REGISTRIES: WHERE DO WE GO FROM HERE?

Presentation
Elaine B. Yu, Head of Evidence for Access BioOncology, Genentech, Inc., South San Francisco, CA, USA
Joshua M Noone, Director, Global Evidence, Value and Access, Ipsos Healthcare, New York, NY, USA
Christopher M Blanchette, Senior Vice President, Global Evidence, Value and Access, Ipsos Healthcare, New York, NY, USA
Emily Zacherle, Senior Research Manager, Global Evidence, Value and Access, Ipsos Healthcare, New York, NY, USA
Jeffrey Vernice, Senior Director, Analytics Business Partner and Data Science, Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 2018, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 2018 – Baltimore, MD, USA
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS

ISPOR WOMEN IN HEOR MEETING

ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP MEETING

ISPOR GENERAL SPECIAL INTEREST GROUP MEETING

ISPOR BIOSIMILAR SPECIAL INTEREST GROUP MEETING

ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP MEETING

ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP MEETING

STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.